ESR1 and breast cancer: The transition in uPAR signaling from transient and uPA-dependent to sustained and autonomous provides a selective advantage for ER+ breast cancer cells in the absence of E2, thereby serving as an escape pathway for breast cancer cells from ERα-targeting therapeutics equivalent to that provided by HER2 overexpression [34].